License Funding and Other Agreements Related to the CVR - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended			12 Months Ended
	Oct. 31, 2020	Feb. 28, 2021	Nov. 30, 2020	May 31, 2019	Dec. 31, 2021	Mar. 23, 2017
Research And Development Arrangement Contract To Perform For Others [Line Items]
Estimated fair value of the CVR liability					$ 0
National Institute of Health
Research And Development Arrangement Contract To Perform For Others [Line Items]
Grant term				5 years
Grants receivable				$ 1,500
Qualifying expenses					500
Qualifying Expenses On Cumulative Basis					1,300
National Institute of Health | Research Funding Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Qualifying expenses					400
Qualifying Expenses On Cumulative Basis					1,300
Contingent Value Rights Agreement | C O V I D19
Research And Development Arrangement Contract To Perform For Others [Line Items]
Total fees and expenses related to clinical trials	$ 1,100				3,000
Increase decrease in estimated fair value of CVR liability			$ 400
Estimated fair value of the CVR liability			$ 600		$ 0
Post Exposure Prophylaxis Description		In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment
Novartis License Agreement | Novartis International Pharmaceutical Ltd.
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement termination description					The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days’ prior written notice.
Novartis License Agreement | Novartis International Pharmaceutical Ltd. | Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Aggregate amount payable upon satisfaction of clinical milestones						$ 4,300
Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved						24,000
Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved						18,000
Aggregate amount payable upon satisfaction of commercial milestones						$ 125,000